EMA strengthens safety measures for cenobmate in epilepsy

The European Medicines Agency (EMA) is tightening safety conditions for Ontozry, an antiepileptic drug containing cenobmate.

Published 26sem1 sourceupdated 14sem
Lire en français
≈ 20s

The fact

These new rules aim to minimize the risk of serious adverse effects in treated patients.

The drug remains available but under strict clinical and biological monitoring.

Click the link to read an article on the topic:
Explore this topic
What if you saw the whole news differently?Factae cross-checks hundreds of sources worldwide to keep only the fact, no opinion. Explore the front page.
Follow topic →
Auto-synthesis from 1 media source · identified on May 22, 2026
← Back to home
Discover

Read more

All sante →